Zobrazeno 1 - 2
of 2
pro vyhledávání: '"MM Santandreu Esterlich"'
Autor:
JR Urgeles Planella, P Rovira Torres, MM Santandreu Esterlich, M Gomez Zamora, O. Delgado Sánchez, Maximiliano Ortiz, E Rodriguez Campos, A Jimenez Portilla, A Gomez Lobon
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Alirocumab and Evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) that have been authorised by the Autonomous Health Service under the following conditions: uncontrolled familial hypercholesterolaemia (FH) wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c33e872c9137f4abdeac27984cc376
https://doi.org/10.1136/ejhpharm-2019-eahpconf.176
https://doi.org/10.1136/ejhpharm-2019-eahpconf.176
Autor:
P Rovira Torres, C Perello Alomar, M Castro Manzanares, M Gomez Zamora, A Gomez Lobon, M Ortiz, O. Delgado Sánchez, MM Santandreu Esterlich
Publikováno v:
Eur J Hosp Pharm
Background Secukinumab is a recently approved interleukin 17A inhibitor indicated for the treatment of patients with plaque psoriasis, psoriatic arthritis and ankylosing spondylarthritis. Purpose The aim of the study was to assess the early effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbfdc45e0ce0fd093b63ec697a9cb28
https://europepmc.org/articles/PMC7535515/
https://europepmc.org/articles/PMC7535515/
